StockWatch
·
SAI PARENTERALS LTD · QQ2 FY-2027 · THE CALL

Margins inflect sharply; three new profit centers loading for FY28

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsSAIPARENTSai Parenterals Ltd07 Nov 2026 · 6 min read
Verdict

Buy

confidence 8/10

Credibility

Grade B

H1 EBITDA margin at 17.6% beat 17% guidance; FY27 ₹750 Cr target on track (H1 ₹376 Cr); gross margin guidance >45% delivered 47.5%. But FY28 drivers unmonetized (Prathyak revenue pending, Adelaide TGA deferred).

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Very Optimistic

multi-year

Strong H1 execution ahead of FY27 guidance (₹376 Cr, 17.6% EBITDA margin vs. ₹750 Cr, 17% target). Gross margin expanded sharply to 47.5% (from 40.9% Q1) on inventory management; Australia OTC contracts renewed and expanded (AUD232M term). FY28 inflection credible: Unit III (81% ramp, Dec 2026), Prathyak R&D (Q4 FY27), Adelaide factory (TGA pending Q2 2027). Key risk: Prathyak revenue unquantified and delayed (cost center now, revenue from Q4 FY27 only); Adelaide TGA inspection may slip further; debt at ₹357 Cr expected to peak FY26, decline from FY28 onward.

₹194.9 Cr

Revenue · +null% YoY

₹10.5 Cr

Reported PAT · +null% YoY

Expanding

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

Gross margin hero; raw material cost fell 3% despite 9% revenue growth

MET

Gross margin 47.5% (up from 40.9% Q1), OPM 20.6%, inventory management drove RM cost down

H1 ahead of plan; EBITDA margin already at 17.6%, beating 17% guidance

MET

H1 EBITDA margin 17.6% on INR376 Cr revenue (>50% of ₹750 target); 17% guided, matched/beaten

PAT grew 33% QoQ; profit before tax holding steady despite D&A spike

MET

PAT up 32.7% QoQ to ₹10.5 Cr; D&A rose to ₹25.1 Cr (new capex impact), PBT INR9.9 Cr stable

Unit III ramping complete, Adelaide commissioned Jan 2027 (now slightly delayed)

MET

Unit III starts Dec 2026, ramping Q4+; Adelaide: Jan 2027 target (pushed from baseline due to Iran logistics), TGA Q2 2027

Prathyak to generate own revenue from Q4 FY27

OVERSTATED

Currently non-revenue model (cost center), discussions with clients ongoing; no revenue yet; management deferred FY28 guidance

Earnings quality

What changed since the last call

Deltas vs. the prior call

H1 EBITDA margin delivery vs. guidance

Upgrade

Delivered 17.6% vs. 17% guidance; inventory management and gross margin expansion drove beat

Australia OTC supply contracts

Upgrade

Both 7.5-year EBOS (AUD202M) and 3-year Wesfarmers (AUD30M) renewed with expanded product portfolio and higher value than predecessors

Receivables working capital impact

Downgrade

Spiked to ₹250 Cr (vs. typical 120-day cycle); timing-driven but absorbs cash in H1; expected to normalize Q3-Q4

Prathyak revenue timing

Neutral

Still described as 'non-revenue model' under development; Q4 FY27 target for external R&D contracts, but no revenue booked yet; management deferred guidance to next call

Adelaide facility commissioning

Neutral

Slipped from original Jan 2027 baseline; now expected Jan 2027 (same), TGA Q2 2027 (slippage visible). Iran logistics cited.

The Q&A

Moderate. Analysts pressed on margin sustainability (Heet, Axis), receivables (Amol Rao, Plutus), Prathyak revenue timing (Murali), and cash flow cyclicality (Gopal Bhatt). Management held firm on ₹750 Cr FY27 target, defended >45% gross margin, but deferred FY28 specifics to next call (January 2027). No one question was dodged outright, but Prathyak revenue guidance was deferred rather than estimated, signaling caution.

The exchanges that mattered

Margin sustainability — Heet, Axis Capital

Partial

Gross margin to stay >45%. Q2 was inventory hero (cleared high-cost prior-quarter stock); ongoing RM recovery plus new capacity ramping (Unit III, Adelaide) will sustain. No quantified sales growth guidance for near-term.

Receivables surge — Amol Rao, Plutus Wealth

Answered

Export receivables <120 days, domestic 120-150 days. End-of-quarter sales bunching; will normalize Q3-Q4. One-off timing, not a trend.

Philippines contract clarity — Amol Rao

Answered

Two separate contracts. USD11M is anti-TB (government program, specific requirement), USD14M is regular business (signed pre-IPO). 11 molecules added this quarter; USD11M and USD14M are distinct.

Prathyak revenue potential — Amol Rao

Dodged

Too early to give numbers. Currently cost center; R&D development spend ongoing. Will transition to revenue model from Q4 FY27 onward as external contracts start. Next call will have guidance.

US FDA strategy — Murali (analyst name withheld in transcript)

Answered

EU GMP and Southeast Asia, Latin America, Middle East focus for 2-3 years. US FDA launch at least 2-3 years out. But keeping option open if CMO client demands own manufacturing; flexible to local market needs.

FY28 guidance — Murali

Dodged

Too pre-emptive to give FY28 numbers now. Will release in next earnings call (January–February 2027). Probably the next three years will have substantial increases, but official guidance next call.

Cash flow cyclicality — Gopal Bhatt, Baroda BNP Paribas

Answered

H1 FY26 was standalone (Noumed not consolidated). This year has 4 subsidiaries, different picture. IPO cash on books (₹110–113 Cr). OFS used for capex. Cash will normalize by year-end; major outflows are CapEx which are tracked separately.

Three-year strategy — Bhavika Singhvi, Niveshaay

Answered

Three-year vision: Saicriti facility with 154M capacity, backward integration for all dosages, new molecule capabilities (mAbs, biosimilars from 2027–28). All dosages, all geographies, but challenges are project integration and management scaling. Targeting 2030 for full integration; 30 years CDMO experience gives confidence but complexity is real.

Guidance

Forward guidance and management's confidence

FY27 INR750 Cr full-year (H1:H2 split 45:55)

High

H1 achieved INR376 Cr (50% of target, exceeding 45% split). H2 needs ₹374 Cr; management says 'very, very comfortably crossing that.' On track.

EBITDA margin 17% maintained for FY27

High

H1 EBITDA margin 17.6%, exceeding 17% guidance. Driven by gross margin expansion and operational leverage.

Gross margin >45% (moderate level, next quarters)

High

Q2 delivered 47.5%; management expects to hold >45% as inventory normalization continues and Unit III/Adelaide ramp.

Saicriti Pharma INR215 Cr total project cost

High

Sai contribution INR83.83 Cr (already invested INR15 Cr in Prathyak, INR98.8 more in Saicriti); facility on track for Jul 2027 completion

Adelaide facility AUD46 Cr invested, AUD20 Cr grant received

Medium

Commissioning delayed to Jan 2027 (from baseline); TGA inspection Q2 2027. Iran logistics caused initial slip.

Risks the call surfaced

Ranked by how much they should concern a holder

Regulatory & TGA delays

High

Saicriti completion (Jul 2027) and Adelaide TGA inspection (Q2 2027) are path-to-revenue for new capacity. Delays push profitability upside into FY29. Iran logistics has already caused one slip.

Prathyak revenue unmonetized

High

Prathyak Labs (60% stake acquired 15 Sep 2026) currently a cost center. External R&D revenue model promised from Q4 FY27, but no contracts booked yet. Management deferred FY28 revenue guidance, signaling caution. If external clients don't materialize, CapEx spent on R&D assets may not yield returns.

Working capital pressure

Medium

Receivables spiked to ₹250 Cr (Q2), up from implied ~₹160 Cr (Q1, 30 days). Management attributes to end-of-quarter timing, expects normalization by Q4. But if export/institutional customers delay payments, OCF could turn negative despite strong profitability.

Debt servicing & leverage

Medium

Debt at ₹357 Cr (Sept 2026), up from ₹320 Cr (March 2026). Management expects FY26 to be peak debt year, with decline from FY28 onward as new facilities generate EBITDA. Execution risk if margin expansion stalls or capex delays push debt repayment into FY28+. Current D/E ratio not disclosed.

Australia manufacturing transition risk

Medium

Adelaide facility will move Noumed outsourced volumes in-house from Q1 FY28, converting distribution margin to manufacturing margin (higher upside, but execution risk). Australia accounts for 76% of export revenue. TGA inspection deferred to Q2 2027. Any delays in commissioning or regulatory approval could disrupt Australia supply and margin expansion narrative.

Management

Score 8/10. Clear, granular on capex and contract details (Mark Thulborne gave specific AUD values, timelines). Anil Kumar defensive on FY28 guidance ('too pre-emptive'), deferring to next call. Acknowledged execution challenges (Iran logistics, integration complexity) without sugar-coating. H1 EBITDA margin at 17.6% beat 17% guidance; gross margin expanded 660 bps (inventory mgmt). H1 revenue ₹376 Cr on track for ₹750 Cr FY27 target. Capex visible and advancing (Saicriti, Unit III, Adelaide). Noumed consolidation integrated by Q2. Track record: B+ (on-track delivery, no prior misses cited, but new capex still in construction phase).

What to watch next
  • 1 · Dec 2026

    Unit III Bhongir ramp-up begins; 81% capacity increase

  • 2 · Q4 FY27 (Jan–Mar 2027)

    Prathyak Labs begins external R&D revenue; Saicriti on track for Jul 2027 completion

  • 3 · Jan 2027

    Adelaide factory commissioned (TGA inspection Q2 2027); Australia outsourced volumes move in-house

Key risk: Prathyak revenue unquantified and delayed (cost center now, revenue from Q4 FY27 only); Adelaide TGA inspection may slip further; debt at ₹357 Cr expected to peak FY26, decline from FY28 onward.

Informational and educational content only. Not investment advice.